Article thumbnail

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients

By Sebastian J. C. M. M. Neggers, Wouter W. de Herder, Richard A. Feelders and A. J. van der Lely

Abstract

The efficacy of combined treatment in active acromegaly with both long-acting somatostatin analogs (SRIF) and pegvisomant (PEG-V) has been well established. The aim was to describe the PEG-V dose reductions after the conversion from daily PEG-V to combination treatment. To clarify the individual beneficial and adverse effects, in two acromegaly patients, who only normalized their insulin like growth factor (IGF-I) levels with high-dose pegvisomant therapy. We present two cases of a 31 and 44 years old male with gigantism and acromegaly that were controlled subsequently by surgery, radiotherapy, SRIF analogs and daily PEG-V treatment. They were converted to combined treatment of monthly SSA and (twice) weekly PEG-V. High dose SSA treatment was added while the PEG-V dose was decreased during carful monitoring of the IGF-I. After switching from PEG-V monotherapy to SRIF analogs plus pegvisomant combination therapy IGF-I remained normal. However, the necessary PEG-V dose, to normalize IGF-I differed significantly between these two patients. One patient needed twice weekly 100 mg, the second needed 60 mg once weekly on top of their monthly lanreotide Autosolution injections of 120 mg. The weekly dose reduction was 80 and 150 mg. After the introducing of lanreotide, fasting glucose and glycosylated haemoglobin concentrations increased. Diabetic medication had to be introduced or increased. No changes in liver tests or in pituitary adenoma size were observed. In these two patients, PEG-V in combination with long-acting SRIF analogs was as effective as PEG-V monotherapy in normalizing IGF-I levels, although significant dose-reductions in PEG-V could be achieved. However, there seems to be a wide variation in the reduction of PEG-V dose, which can be obtained after conversion to combined treatment

Topics: Article
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:3146981
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
  2. (2008). A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.
  3. (2009). A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
  4. (2004). A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
  5. (2009). Acromegaly pathogenesis and treatment.
  6. (2009). ACROSTUDY: the first 5 years.
  7. (1987). Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.
  8. (2004). Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
  9. (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
  10. (2009). Combined treatment for acromegaly with longacting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
  11. (2005). Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
  12. (2008). Function and expression of somatostatin receptors of the endocrine pancreas.
  13. (2004). Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
  14. (2000). Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation.
  15. (1994). Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion.
  16. (2008). Long-term effects of pegvisomant in patients with acromegaly. Nat clin pract 4(6):324–332
  17. (2007). Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
  18. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
  19. (2008). Mortality in acromegaly: a metaanalysis.
  20. (2008). Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.
  21. (2008). Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
  22. (2009). Radiotherapy and radiosurgery in acromegaly.
  23. (2004). Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3).
  24. (2009). Somatostatin analog and pegvisomant combination therapy for acromegaly.
  25. (1982). Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
  26. (1993). The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
  27. (2010). Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study.